Springer Nature OAopen access
Exposure-response analyses for belantamab mafodotin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma from DREAMM-6 Arm B and DREAMM-7
Biomedicine, Biomedicine, general, Cancer Research, Epidemiology, Molecular Medicine, Oncology
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 299087
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.